Recent Updates
Recently added Catalysts

Cadre Holdings, Inc.

CDREFDA catalysts, PDUFA dates & pipeline intelligence
$32.1
▼ -1.33 · -3.96%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full CDRE financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $24.0752W HIGH $48.76
Volume
268.80 K
Value Traded
8.56 M
Short % Float
6.86%
Days to Cover
4.6
-5.66%Week
+19.12%1 Month
-3.17%3 Month
+10.16%6 Month

Cash Data

Unlock CDRE cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
1.38 B
EPS (TTM)
0.96
P/E Ratio
33.67
Ent. Value
1.69 B
Total Shares
42.92 M
Float Shares
31.29 M
Insiders
27.10%
Institutions
74.05%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every CDRE catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

CDRE Catalyst Timeline

Dated clinical, regulatory and corporate events for Cadre Holdings, Inc.

Unlock the full CDRE catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How CDRE actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all CDRE historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

Cadre Holdings, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every CDRE program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every CDRE trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock CDRE insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Williams BradOfficer (PRESIDENT)Option 200,000 265,081 held$0.00 11/08/2026
Unlock the full CDRE insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in CDRE for Q2 2026.
Unlock every fund holding CDRE
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in CDRE
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see CDRE ownership
Insider and institutional ownership, quarter by quarter.

CDRE Short Interest

Shares sold short, counted twice a month.

6.86%
Short % of Float
of tradable shares sold short
2.1M
Shares Sold Short
+13.8% vs prior count
4.6 Moderate
Days to Cover
trading days of normal volume to buy every short share back
471.8K
Avg Daily Volume
the average used for days to cover
Unlock CDRE short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock CDRE option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live CDRE option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock CDRE options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How CDRE ranks across every disease it competes in

Competitive Position is a premium feature
See how CDRE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

CDRE News

-CDRE
Nov 16, 2026
CDREGeneral
▼ -4%today

Cadre Holdings Announces Chief Financial Officer Transition

Cadre Holdings announced the resignation of CFO Blaine Browers, effective year-end, to join another company. CEO Warren Kanders praised Browers for his contributions, including the company's public offering and acquisitions. Chad Appleby will serve as Interim CFO while a search for a permanent replacement begins. The company reaffirmed its financial guidance for 2026.

Read more →
-CDRE
Nov 4, 2026
CDREGeneral

Cadre Holdings Reports Third Quarter 2026 Financial Results

Cadre Holdings reported strong third-quarter results for 2026, with net sales reaching $202.9 million, a 30% increase from the previous year. Net income rose 46% to $16.0 million, while adjusted EBITDA reached $41.1 million, reflecting an expanded margin of 20.2%. The company raised its full-year guidance and announced a $100 million stock repurchase program.

Read more →
-CDRE
Oct 22, 2026
CDREGeneral

Cadre Holdings Announces Third Quarter 2026 Earnings and Conference Call Information

Cadre Holdings, Inc. will announce its third quarter 2026 earnings on November 4, 2026. A conference call is scheduled for November 5, 2026, at 10:00 a.m. ET, featuring remarks from top executives. Participants can join by phone or listen to a live webcast on the company's website.

Read more →
-CDRE
Oct 20, 2026
CDREGeneral

Cadre Holdings Declares Quarterly Dividend of $0.10 Per Share

Cadre Holdings, Inc. announced a quarterly cash dividend of $0.10 per share, amounting to $0.40 annually. The dividend will be paid on November 13, 2026, to shareholders recorded by October 30, 2026. Future dividends will depend on the Board's discretion. Cadre is a leader in safety equipment manufacturing.

Read more →
-CDRE
Aug 26, 2026
CDREConferences/Events

Cadre Holdings Announces Participation at Upcoming Investor Conferences

Cadre Holdings, Inc. announced its participation in several investor conferences in New York on September 9 and 10, 2026. President Brad Williams and CFO Blaine Browers will present at the Jefferies Industrials Conference and the B Riley Consumer & TMT Conference. The presentations will be accessible via live webcasts, and management will hold investor meetings.

Read more →
-CDRE
Aug 5, 2026
CDREGeneral
▲ +12.9%on this news

Cadre Holdings Reports Second Quarter 2026 Financial Results

Cadre Holdings reported strong Q2 2026 results, with net sales of $207.1 million, a 32% increase from the previous year. The company raised its full-year guidance, expecting net sales between $749 million and $769 million. However, net income fell to $11.4 million due to higher expenses. The orders backlog also reached a record $368 million.

Read more →
-CDRE
Jul 23, 2026
CDREConferences/Events

Cadre Holdings Announces Second Quarter 2026 Earnings and Conference Call Information

Cadre Holdings, Inc. announced it will release its financial results for the second quarter of 2026 on August 5, 2026. A conference call featuring CEO Warren Kanders and other executives is scheduled for August 6, 2026, at 10:00 a.m. ET. The call will be accessible via phone and a live webcast.

Read more →
-CDRE
Jun 2, 2026
CDREGeneral

Cadre Holdings Subsidiary Safariland Selected as Ballistic Provider for FBI Armor Contract

Cadre Holdings' subsidiary Safariland has been awarded a five-year, $61 million contract by the FBI for its SX™ HP ballistic panel, which will be integrated into the Overt Armor Kit. This selection highlights the product's competitive edge and reflects Cadre's commitment to innovation in protective equipment. The contract also opens opportunities for additional federal law enforcement business.

Read more →
-CDRE
May 11, 2026
CDREGeneral
▲ +5.1%on this news

Cadre Holdings Reports First Quarter 2026 Financial Results

Cadre Holdings reported a strong first quarter for 2026, with net sales growing by 19% year-over-year to $155.4 million. They achieved a record orders backlog of $355 million, bolstered by recent acquisitions and heightened demand in safety equipment. However, net income fell to $2 million, marking a significant decrease compared to the previous year's quarter. Despite these challenges, the company reaffirmed its full-year guidance, reflecting confidence in its growth trajectory and strategic positioning in the market.

Read more →
-CDRE
Apr 29, 2026
CDREGeneral
▲ +8.3%on this news

Cadre Holdings Announces First Quarter 2026 Earnings and Conference Call Information

Cadre Holdings, Inc. announced its plans to release first quarter 2026 financial results on May 11, 2026. A conference call is scheduled for May 12, 2026, featuring key executives. The call will be accessible via phone and a live webcast. A replay will be available until May 26, 2026.

Read more →
-CDRE
Mar 26, 2026
CDREGeneral

Cadre Holdings to Acquire Assets of Tedder Industries, Including Alien Gear Holsters

Cadre Holdings, Inc. announced its acquisition of Alien Gear Holsters for $10.3 million through a bankruptcy auction. This move is expected to enhance Cadre's product offerings and leverage Alien Gear's established market presence. The transaction is subject to regulatory approvals and is anticipated to close in the second quarter of 2026.

Read more →
-CDRE
Mar 10, 2026
CDREGeneral
▼ -7.5%on this news· ran to -28% by day 3

Cadre Holdings Reports Fourth Quarter and Full Year 2025 Financial Results

Cadre Holdings announced its fourth quarter and full year 2025 financial results, reporting net sales of $610.3 million and a gross margin of 42.5%. The company achieved record adjusted EBITDA for the third consecutive year and anticipates further growth in 2026, with projected net sales of $736 to $758 million. However, there was a decline in net income and gross profit margin for the fourth quarter, attributed to previous high shipment levels and rising costs. The company remains focused on acquisitions to enhance its market leadership in safety products.

Read more →
-CDRE
Nov 4, 2025
CDREGeneral

Cadre Holdings Reports Third Quarter 2025 Financial Results

Cadre Holdings has reported strong financial results for the third quarter of 2025, with net sales rising by 42% and gross profit climbing by 66% year-over-year. Adjusted EBITDA also increased significantly to $29.8 million, reflecting the company's growth strategy, including a recent acquisition of TYR Tactical. The firm reported a marked improvement in backlog and profitability, although higher administrative expenses and increased compensation costs have posed challenges. As Cadre looks to broaden its market presence, it remains focused on pursuing further acquisitions and leveraging strong demand in its core markets.

Read more →
-CDRE
Oct 29, 2025
CDREGeneral

ACQUISITION OVERVIEW

Cadre has announced the acquisition of TYR Tactical for a total consideration of $175 million, which includes $150 million in cash and $25 million in stock. This strategic move is designed to capitalize on new growth opportunities in high-value markets such as European military and defense sectors. The acquisition aims to provide significant operational synergies and further strengthen Cadre's position in the tactical gear market. However, there are risks associated with the completion of this acquisition and the integration process that could impact the company's future performance.

Read more →
-CDRE
Oct 8, 2025
CDREConferences/Events

INVESTOR DAY

Cadre Nuclear Group showcased its strategic initiatives aimed at supporting the nuclear energy sector during an investor day. Key highlights included a focus on environmental management, national security, and the company's commitment to enhancing nuclear safety and operations. The organization emphasized its rapid growth potential through recent acquisitions and investments, which position it favorably in an evolving market influenced by demand for reliable energy sources. Upcoming projects are expected to capitalize on government mandates and private investments supporting nuclear technologies.

Read more →
-CDRE
Aug 5, 2025
CDREGeneral

Cadre Holdings Reports Second Quarter 2025 Financial Results

Cadre Holdings, Inc. reported a strong performance in the second quarter of 2025, with net sales and gross profit rising by 9% and 10% year-over-year, respectively. The company highlighted robust demand for its safety equipment across multiple markets, including law enforcement and nuclear safety sectors. Despite a slight decline in net income due to acquisition costs, the outlook remains positive driven by strategic acquisitions and a solid financial position. Cadre anticipates revenue growth due to increasing environmental and defense-related demands, although new tariffs may impact operations.

Read more →
-CDRE
May 6, 2025
CDREGeneral

Cadre Holdings Reports First Quarter 2025 Financial Results Capitalizes on Continued Strong Demand for Mission Critical Safety Equipment

Cadre Holdings, Inc. reported its first-quarter financial results for 2025, highlighting strong demand for its safety equipment. The company generated net sales of $130.1 million, showing resilience despite timing issues with large orders. The acquisition of Carr's Engineering Division is set to enhance Cadre's capabilities in the nuclear safety sector. Forward guidance indicates optimism, with anticipated net sales between $618 million and $648 million for the year.

Read more →
-CDRE
Mar 11, 2025
CDREGeneral

Cadre Holdings Reports Fourth Quarter and Full Year 2024 Financial Results

Cadre Holdings reported strong financial results for the fourth quarter and full year of 2024, achieving net sales of $568 million and a gross margin of 41.1%. The company experienced notable net income of $36 million, although it faced rising selling and administrative expenses. Looking ahead, Cadre expects to generate net sales between $572 million and $601 million in 2025, propelled by recent acquisitions and ongoing positive demand in their product segments. CEO Warren Kanders highlighted the company's commitment to public safety and their strategic growth approach in nuclear safety markets.

Read more →

About Cadre Holdings, Inc.

Jacksonville, FL 2,533 employees cadre-holdings.com
Headquarters13386 INTERNATIONAL PKWY, JACKSONVILLE, FL, 32218
BIOPHARMAWATCH ELITE
Trade the next CDRE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime